GSK Ends Advair Co-Promotion With Mistubishi Tanabe
This article was originally published in PharmAsia News
GlaxoSmithKline will end a co-promotion deal with Mitsubishi Tanabe for Advair (fluticasone/salmeterol) by the end of July. Starting in August, GSK will be the sole marketer of the drug in Japan. The co-promotion started last April when GSK signed up Mitsubishi to promote Advair as the top treatment for chronic obstructive pulmonary disease in Japan. One year later, GSK said it had achieved the goal demonstrated by raised product awareness among medical facilities. Advair Japanese domestic sales reached ¥37.6 billion last year. The drug faces increasing competition in the dry powder inhaler market from Symbicort (budesonide/formoterol), which is being co-promoted by AstraZeneca and Astellas. Launched in January, Symbicort sales reached ¥1.5 billion at the end of March. (Click here for more - Japanese language) "GSK To Solely Market Adoair From August" - CB News (7/2/2010)
You may also be interested in...
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.